Active immunization of Merino ewe lambs with recombinant bovine alpha inhibin advances puberty and increases ovulation rate

Trends in recombinant protein use in animal production

Recombinant technologies have made possible the production of a broad catalogue of proteins of interest, including those used for animal production. The most widely studied proteins for the animal sector are those with an important role in reproduction, feed efficiency, and health. Nowadays, mammalian cells and fungi are the preferred choice for recombinant production of hormones for reproductive purposes and fibrolytic enzymes to enhance animal performance, respectively. However, the development of low-cost products is a priority, particularly in livestock. The study of cell factories such as yeast and bacteria has notably increased in the last decades to make the new developed reproductive hormones and fibrolytic enzymes a real alternative to the marketed ones. Important efforts have also been invested to developing new recombinant strategies for prevention and therapy, including passive immunization and modulation of the immune system. This offers the possibility to reduce the use of antibiotics by controlling physiological processes and improve the efficacy of preventing infections. Thus, nowadays different recombinant fibrolytic enzymes, hormones, and therapeutic molecules with optimized properties have been successfully produced through cost-effective processes using microbial cell factories. However, despite the important achievements for reducing protein production expenses, alternative strategies to further reduce these costs are still required. In this context, it is necessary to make a giant leap towards the use of novel strategies, such as nanotechnology, that combined with recombinant technology would make recombinant molecules affordable for animal industry.

The effect of exogenous gonadotropins on ovarian function in goats actively immunized against inhibin

The aim of this investigation was to compare the ovarian response to superovulatory treatments in does before and after inhibin immunization, with a view to optimizing the superovulatory potential of the caprine ovary. To avoid interference by the ovarian cycle, the experiment was conducted out-of-season. At the onset of the experiment 48 does were subjected to treatment with an sc implant of the progestogen norgestomet, combined with a gonadotropin; eight does each received a single injection of 1200 IU eCG, 400 IU eCG or 2 mL physiological saline (control) or six injections (at 12 h intervals) constituting 16 or 5.4 AU pFSH. The does were mated and subjected to embryo collection 6 to 7 d later. Throughout the experiment ovarian function (by ultrasonography) and plasma levels of inhibin antibodies and progesterone were monitored. Of 40 does treated during the first part of the experiment, 48% showed estrus. The ovarian response in does treated with a high or low dose of eCG or a low dose of pFSH was barely in excess of the ovarian response in the saline-treated controls, whereas a superovulatory dose of pFSH (16 AU) gave a satisfactory response of, on average, 14.5 ovulations (yielding 8.8 flushed ova and embryos). Immediately after the does had been subjected to embryo collection they were actively immunized against inhibin by administering two injections of a recombinant α-subunit of ovine inhibin at four week intervals. All immunized does produced antibodies with the maximal titer reached two weeks after the second injection. Groups of immunized does were subjected to the same gonadotropin treatments as before (avoiding allocation of individuals to the same treatments). This time all does showed estrous symptoms. The ovulatory response to the various treatments, including the saline controls, was virtually identical, the overall average being 21.8 follicles and 9.1 ovulations. The average embryo yield per doe was 5.7. The results imply that inhibin acted as the key factor in determining the ovulatory response since no impact of any of the supplementary gonadotropins was noted in inhibin-immunized does. This finding gives rise to the notion that inhibin antibodies may act primarily by an intraovarian paracrine action rather than by reducing the suppressive action of inhibin on pituitary FSH release. Further, these findings confirm earlier reports that eCG is less suitable than FSH for inducing superovulation in goats, and indicate that active immunization against inhibin may be considered a viable alternative to using exogenous gonadotropin for inducing superovulation in goats.

The long-term effect of active immunization against inhibin in goats

This experiment addresses the long-term effect of active immunization of goats against a recombinant ovine inhibin alpha subunit (roIHN-alpha). In late anestrus 100microg of roINH-alpha was administered to 40 pluriparous Boer goat does, followed, 4 weeks later, by a booster injection. Weekly blood samples were drawn to monitor the inhibin binding capacity with the aid of a radio-tracer binding assay. From the onset until 48h after the end of each estrus, follicular development and ovulation rate were monitored at 24h intervals by transrectal ultrasonography. Beginning in August and continuing into January, does were mated at every other estrus, and submitted to transcervical embryo collection. Seven months after the first immunization, the does were mated again and permitted to carry to term. All immunized does produced inhibin antibodies, an elevated titre being first detected 2 weeks after primary immunization. Maximum titres were reached after 6 weeks, i.e. 2 weeks after the booster injection. Thereafter, in the course of the following 32 weeks, the titre subsided gradually. The does started cycling by mid-August. At that stage the average number of follicles more than 4mm in diameter, ovulations and total embryos and ova recovered were 14.7 (+/-2.3), 5.3 (+/-0.7) and 4.4 (+/-1.0), respectively. A steady decline followed and in January the corresponding means were: 5.2 (+/-0.6) follicles, 3.1 (+/-0.6) ovulations and 1.2 (+/-0.4) embryos and ova recovered. When mated toward the end of the breeding season, 85% of the does became pregnant to the first mating and 73% went to term. Healthy kids were born, the average litter size being 2.2 (+/-0.1). In conclusion, immunization of goats against a recombinant inhibin alpha-subunit proved to be a practicable means of producing embryos for transfer purposes. After about half a year, when the inhibin antibody titre has subsided, it is possible to return the does to the breeding flock without risking complications with normal breeding activity.

Immunization of Goats against Inhibin Increased Follicular Development and Ovulation Rate

In the present study, two experiments were conducted to induce superovulation in goats using passive and active immunization against inhibin. In the first experiment, two groups of goats were given an intravenous injection of either 10 ml normal goat serum (control; n=6) or inhibin antiserum developed against [Tyro30]-inhibin alpha (1-30) (passively immunized; n=6) 48 h before treatment with PGF2alpha. In the second experiment, two groups of goats were immunized with inhibin vaccine (actively immunized; n=5) or Freund's adjuvant (control; n=5) followed by three booster immunizations at 4 week intervals. Blood samples were collected for determination of FSH, LH, estradiol-17beta, and progesterone. Ultrasonography was used to determine ovarian activity at PGF2alpha injection and ovulation rate one week after estrus. In both experiments, there was a significant increase in plasma FSH concentration compared with the controls. However, the pattern of the FSH levels was different between the passively and actively immunized goats. The numbers of follicles in passively and actively immunized goats (22.4 +/- 2.3 and 18.6 +/- 2.1, respectively) were significantly greater than those in the controls (2.6 +/- 0.4 and 2.3 +/- 0.4, respectively). In addition, the ovulation rate was greater in the immunized animals compared with the controls. Therefore, either passive or active immunization against inhibin could be used to induce superovulation in goats.

Developmental changes of plasma inhibin, gonadotropins, steroid hormones, and thyroid hormones in male and female Shao ducks

Plasma samples from developing male and female Shao ducks were assayed for immunoreactive (ir-) inhibin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), steroid hormones, and thyroid hormones. In the male, plasma ir-inhibin significantly increased between 75 and 155 days posthatch, and then decreased slightly at day 165. Plasma FSH of male ducks decreased from day 35 to day 55, followed by progressive elevation until day 95. Plasma FSH of male ducks fell significantly at days 135 and 165, while plasma ir-inhibin rose to high level. In female ducks, plasma ir-inhibin remained low until the start of lay, and thereafter significantly increased at day 135. Plasma FSH fluctuated before day 95 and significantly rose at day 115, and decreased thereafter. In males, plasma LH did not vary significantly before day 135, however, plasma testosterone significantly increased from day 95 onwards. No changes in plasma LH were observed during development of female ducks. Plasma estradiol-17beta gradually increased reaching a peak level at day 135. Plasma progesterone did not vary significantly before day 135 and thereafter significantly increased. Both sexes showed a similar pattern in changes of plasma thyroid hormones during sexual development. There was a significant increase in plasma thyroxine (T4) at day 95, thereafter decreased. Plasma triiodothyronine (T3) was at high level at the earlier stage of development and significantly decreased at day 55. Significant increase in plasma T3 in male and female ducks was observed at 135 and 115 days, respectively. In conclusion, these results demonstrated that the rise in inhibin is correlated with age of sexual maturity in the female while the rise in inhibin significantly precedes sexual maturity in the male. There was a progressive increase in plasma steroid hormones towards sexual maturity, and there was no sex difference in the time course of thyroid hormones.

Changes in plasma inhibin A levels during sexual maturation in the female chicken and the effects of active immunization against inhibin alpha-subunit on reproductive hormone profiles and ovarian function

Inhibins and activins are firmly implicated in the control of pituitary FSH secretion and ovarian follicular development in mammals. As in mammals, inhibin A and activin A are expressed in the preovulatory follicles of birds, and a defined ovulation cycle for inhibin A has recently been demonstrated in the laying hen. To investigate further the role of inhibin-related proteins in developing pullets, circulating concentrations of inhibin A, inhibin B, total immunoreactive inhibin alpha-subunit (ir-alpha), activin A, LH, FSH, and progesterone were measured from the juvenile state through to sexual maturity in 22 birds. In the 11 birds assigned to control groups, plasma inhibin A levels were low from 7 to 13 wk of age rising about threefold to a peak at Week 19 after which levels fell slightly to a plateau level characteristic of adult hens. Plasma inhibin A levels were negatively correlated with FSH (r = -0. 33; P: < 0.001) and positively correlated with progesterone (r = 0. 67; P: < 0.001) and ir-alpha (r = 0.53; P: < 0.001). Plasma ir-alpha levels were much higher than inhibin A levels although the relative differences varied with age. Plasma levels of inhibin B and activin A were below assay detection limits at all times. The remaining group of 11 birds was actively immunized (IMM) against a synthetic chicken inhibin alpha-subunit peptide (amino acids 1-26). The IMM generated circulating antibodies that bound native bovine inhibin A but altered neither plasma FSH nor progesterone levels relative to control birds at any stage of development nor the timing of first oviposition in week 19. Apart from a transient decline 1 wk after primary IMM, plasma LH concentrations did not differ from controls. Comparison of the numbers and size-class distribution of ovarian follicles at 29 wk showed an approximate twofold increase in the number of 8- to 9.9-mm-diameter follicles (control; 1.82 +/- 0.44 vs. IMM; 3.91 +/- 0.89; P: < 0.05), a size class that corresponds to follicles that have just joined the preovulatory hierarchy. The numbers of growing follicles in other size-classes and the sizes of hierarchical F(1)-F(7) follicles were not altered by IMM. However, the number of postovulatory follicles increased (control 3.73 +/- 0. 20 vs. IMM 5.55 +/- 0.28; P: < 0.01), and significantly more (P: < 0. 02) immunized hens laid two eggs within a 24-h period on at least one occasion (control 1 of 11 vs. IMM 9 of 11). The IMM increased (P: < 0.05) activin A content of F(1) and F(2) theca layers and decreased (P: < 0.05) activin A content in F(3) and F(4) granulosa layers, raising the possibility of a local intraovarian role of activin in mediating the response to IMM. These findings support a role for inhibin A in regulating the entry of follicles into the preovulatory hierarchy in the chicken, although further studies are required to establish the mechanism by which inhibin IMM increases the rate of follicle selection and ovulation without raising plasma FSH.

Production of a genetically engineered inhibin vaccine

The goal of this research was to synthesize a chimeric ovalbumin/inhibin antigen using recombinant techniques. Antigenic epitopes of the translated product from an ovalbumin cDNA were mapped using computer modeling techniques. The corresponding nucleotide sequences of ovalbumin epitopes were examined for unique restriction sites to allow insertion of a synthetic bovine inhibin alpha gene fragment which encoded the first 26 amino acids. A plasmid (pETOI-8) was synthesized which contained the chimeric ovalbumin/inhibin alpha 1-26 gene. A 46 kDa recombinant protein (ovalin) was produced from BL21 (DE3) Escherichia coli cells containing pETOI-8 that was identified with anti-ovalbumin and anti-inhibin alpha 1-26 antisera. Rabbits were immunized subcutaneously in four sites along the back against ovalbumin (n = 3), crude ovalin (n = 3), or gel-purified ovalin (n = 3) at week 0, 4, 7, and 18. Primary and booster immunizations contained ca 300 micrograms of antigen emulsified in complete Freund's adjuvant and incomplete Freund's adjuvant, respectively. Blood samples collected at week 0, 6, 8, and 19 were evaluated for their ability to bind ovalbumin, 32 kDa bovine inhibin and bovine inhibin alpha 1-26 using ELISA. Mean anti-ovalbumin titers at week 19 were 1:100000 in rabbits immunized against ovalbumin or crude ovalin, and 1:23333 in rabbits immunized against gel-purified ovalin. Anti-inhibin and anti-inhibin alpha 1-26 titers were nonexistent in antisera from pre-immunized rabbits and rabbits immunized against ovalbumin. Mean anti-inhibin titers at week 19 were 1:833 and 1:10000 in rabbits immunized against crude ovalin or gel-purified ovalin, respectively. Mean anti-inhibin alpha 1-26 titers at week 19 were 1:3333 and 1:6666 in rabbits immunized against crude or gel-purified ovalin, respectively. We conclude that genetic engineering of inhibin alpha 1-26 into the antigenic epitopes of ovalbumin provides potential for the development of an anti-inhibin vaccine.

Immunoregulation of mammalian fertility

Fertility management is a global issue of agricultural, medical, economic, and social consequence. Although many methods have been devised to both inhibit and assist reproduction, more acceptable alternatives are needed. Regulation by immune intervention is a promising technology as applied to livestock, pets, wildlife, and human beings. Outcome is dictated by site within the reproductive axis that is targeted. Fertility is suppressed by immunization against gonadotropin-releasing hormone, gonadotropins, prostaglandin F2 alpha, oxytocin, gonadotropin receptors, and gamete/embryonic antigens. It also is possible to lyse gonadal cells with ligand-antibody hybrid molecules. Ovulation rates are enhanced by vaccination with inhibin. Antibodies to sex steroid hormones have yielded mixed results. Perhaps recombinant viral vectors can be used to deliver reproductive immunogens. A new and simple technique to generate sustained autoimmune reactions to hormones and cellular antigens entails direct gene transfer into somatic cells. Evolving advances in reproductive immunology and biotechnology should furnish us with novel nonsurgical contraceptives and profertility agents that can be efficiently and safely implemented.